Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE, RP1 Clinical Trial
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to support research projects that employ state-of-the-art cancer biology approaches and preclinical model systems to investigate the biological effects of radiation emitted by radionuclides used in radiopharmaceutical therapy
| Agency | National Institutes of Health |
|---|---|
| Status | Forecasted |
| Opportunity number | PAR-26-129 |
| Posted date | 03/11/2026 |
| Who can apply | Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions). |
| Assistance Listing (CFDA) | 93.395, 93.394 |
| Description | Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to support research projects that employ state-of-the-art cancer biology approaches and preclinical model systems to investigate the biological effects of radiation emitted by radionuclides used in radiopharmaceutical therapy (RPT). The focus of this initiative is to advance mechanistic understanding of how different forms of radionuclide-emitted radiation affect normal tissues, tumor cells, and the tumor microenvironment, and how these effects can be leveraged to improve therapeutic outcomes. This NOFO will support the Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) program. The overarching goal of STRIPE is to stimulate multidisciplinary research that integrates cancer b |
| Agency contact | Email: STRIPE-ProgramContact@mail.nih.gov |
| Official listing | https://www.grants.gov/search-results-detail/361447 |